{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:34:46Z","timestamp":1770788086059,"version":"3.50.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Purpose<\/jats:title><jats:p>This study investigates the visual outcomes of neovascular age-related macular degeneration (nAMD) patients who developed intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr).<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>We studied 285 eyes of 279 cases diagnosed with nAMD and focused on 18 eyes (6.3%) of 17 cases which developed IOI after IVBr. IVBr was performed either on the initial treatment or for switching of other anti-vascular endothelial growth factor agents during January 2020 to December 2021. We evaluated clinical features and the course of treatment of a 6-month follow-up after IOI occurred.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Of 17 cases, 9 cases were male, 8 cases were female. Baseline logarithm of the minimum angle of resolution(logMAR) best-corrected visual acuity (BCVA) was 0.36, BCVA before IOI occurred was 0.30, and BCVA when IOI occurred was 0.43. 16 eyes (88.9%) had symptoms such as visual loss or floaters when IOI occurred. On the other hand, the remaining 2 eyes (11.1%) had no symptoms. 11 eyes (61.1%) had only IOI, while the remaining 7 eyes (38.9%) had IOI and perivascular sheathing. Steroid sub-tenon injection was performed on 1 eye (5.6%), steroid eye drops were used in 11 eyes (61.1%), and 6 eyes (33.3%) were followed-up without treatment. Neovascular AMD recurred in 16 eyes (88.9%) after IOI occurred and were treated with aflibercept. VA at 3 and 6 months after IOI occurred were significantly improved to 0.34 and 0.30, respectively (<jats:italic>P<\/jats:italic>= 0.09 at 3 months and<jats:italic>P<\/jats:italic>= 0.02 at 6 months). The symptoms of patients were improved in all cases. We were able to stop steroid treatment in all cases.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>IOI occurred in 6.3% of nAMD patients after IVBr treatment. All of which showed significant improvement from logMAR of 0.43 to 0.30 with steroid treatment or without any treatment. We should consider the possibility of IOI after IVBr as a complication, however, they have a relatively good prognosis if treated at an early stage.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0302295","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T18:01:38Z","timestamp":1713463298000},"page":"e0302295","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration"],"prefix":"10.1371","volume":"19","author":[{"given":"Kazushi","family":"Hirono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-1329","authenticated-orcid":true,"given":"Maiko","family":"Maruyama-Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"pone.0302295.ref001","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"PJ Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"pone.0302295.ref002","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept(VEGF trap-eye) in wet age-related macular degeneration.","volume":"119","author":"JS Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"pone.0302295.ref003","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"J Mones","year":"2021","journal-title":"Ophthalmology"},{"key":"pone.0302295.ref004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10384-022-00940-1","article-title":"Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration","volume":"66","author":"Y Kitajima","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0302295.ref005","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1038\/s41598-022-12216-2","article-title":"One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy.","volume":"12","author":"A Ito","year":"2022","journal-title":"Scientific Rep"},{"key":"pone.0302295.ref006","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1080\/02713683.2020.1731832","article-title":"Comparison of the efficacy of brolucizumab with natural disease progression in wet AMD using clinical data from the phase III HAWK and HARRIER trials and modelled placebo data","volume":"45","author":"H Agostini","year":"2020","journal-title":"Curr Eye Res"},{"key":"pone.0302295.ref007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"CR Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"pone.0302295.ref008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment.","volume":"5","author":"CR Baumal","year":"2021","journal-title":"Ophthalmol Retina."},{"key":"pone.0302295.ref009","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"SJ Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"pone.0302295.ref010","doi-asserted-by":"crossref","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"A Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"pone.0302295.ref011","first-page":"247412642093086","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab.","author":"A Witkin","year":"2020","journal-title":"J Vitreoretin Dis."},{"key":"pone.0302295.ref012","article-title":"Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity","author":"SSA Kondapalli","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"pone.0302295.ref013","doi-asserted-by":"crossref","first-page":"p259","DOI":"10.1016\/j.ophtha.2019.09.028","article-title":"Retinal and Ophthalmic Artery Occlusions Preferred Practice Pattern (R).","volume":"127","author":"CJ Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"pone.0302295.ref014","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajo.2014.06.019","article-title":"Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes","volume":"158","author":"RA Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"pone.0302295.ref015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bjo.2008.138479","article-title":"Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).","volume":"93","author":"M Georgopoulos","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"pone.0302295.ref016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.65.1.8","article-title":"Factors associated with intraocular inflammation in neovascular age-related macular Degeneration patients treated with brolucizumab","volume":"65","author":"Y Hashimoto","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0302295.ref017","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early experience with brolucizumab treatment of neovascular age-related macular degeneration","volume":"139","author":"AB Enriquez","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"pone.0302295.ref018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from IRIS registry and komodo healthcare map","volume":"140","author":"AM Khanani","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"pone.0302295.ref019","first-page":"16","article-title":"Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration","author":"R Mukai","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"pone.0302295.ref020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0000000000003769","article-title":"Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: a systematic review of real-world evidence.","volume":"43","author":"CC Wykoff","year":"2023","journal-title":"Retina"},{"key":"pone.0302295.ref021","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000526703","article-title":"The importance of imaging to identify early signs of intraocular inflammation expert opinion for brolucizumab","volume":"245","author":"SR Sadda","year":"2022","journal-title":"Ophthalmologica"},{"key":"pone.0302295.ref022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-019-0190-y","article-title":"Optical coherence tomography angiography in uveitis.","volume":"9","author":"P Tranos","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"pone.0302295.ref023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0974-9233.58419","article-title":"Fluorescein and indocyanine green angiography for uveitis.","volume":"16","author":"CP Herbort","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"9","key":"pone.0302295.ref024","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","article-title":"Japan AMD Research Consortium. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study","volume":"259","author":"I Maruko","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"pone.0302295.ref025","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1038\/s41598-022-10578-1","article-title":"One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 macular neovascularization.","volume":"12","author":"H Matsumoto","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0302295.ref026","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"WJ Anderson","year":"2021","journal-title":"Int J Retina Vitreous"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0302295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T15:50:58Z","timestamp":1731772258000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0302295"}},"subtitle":[],"editor":[{"given":"Jiro","family":"Kogo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0302295","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}